FDA approves Genentech's Actemra against rare Still's disease in children

Genentech Inc.’s rheumatoid arthritis drug Actemra was approved Friday by the Food and Drug Administration as a treatment for Still’s disease in children ages 2 or older.
Still’s disease, also known as active systemic juvenile idiopathic arthritis, is a rare, potentially life-threatening disorder that causes severe inflammation throughout the body. It is different from other forms of juvenile idiopathic arthritis by spiking fevers, rash, swelling of lymph nodes, liver and spleen and high white blood cell counts.